Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase iii clinical trial in China

Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase iii clinical trial in China

Background Adolescents and adults who contract chickenpox are at a higher risk of severe complications. Vaccination with the varicella vaccine (VarV) effectively prevents chickenpox.Research design and methods In this phase III, single-center, randomized, double-blind, active-controlled trial, 1,200...

Full description

Saved in:
Bibliographic Details
Main Authors: Yang Zhang, Shiyuan Wang, Guifan Li, Jinhui Shi, Xianyun Chang, Hao Zhang, Fengcai Zhu, Jingxin Li, Hongxing Pan, Jinfang Sun
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Expert Review of Vaccines
Subjects:
Varicella vaccine
phase III
immunogenicity
safety
adolescents
adults
Online Access:https://www.tandfonline.com/doi/10.1080/14760584.2025.2457463
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/14760584.2025.2457463

Similar Items